Registrations have closed.
New Ways of Evaluating the Tumor Immune Microenvironment: From Bench to Bedside
by
187 187 people viewed this event.
T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration.
Additional Details
Etkinlik Ülkesi - United States of America
